Evolution of renal-disease factor APOL1 results in cis and trans orientations at the endoplasmic reticulum that both show cytotoxic effects.

Daria Müller¹, Jürgen Schmitz², Katharina Fischer¹, Daniel Granado¹, Ann-Christin Groh¹, Vanessa Krausel¹, Simona Mareike Lüttgenau¹, Till Maximilian Amelung¹, Hermann Pavenstädt¹ and Thomas Weide¹*

¹ University Hospital of Münster (UKM), Internal Medicine D (MedD), Molecular Nephrology, Albert-Schweitzer-Campus 1 Building A14, 48149 Münster, Germany

² Institute of Experimental Pathology, ZMBE, University of Münster, Von-Esmarch-Str. 56, D-48149 Münster, Germany

Running title: APOL1 evolution results in dual ER orientations

* Corresponding author:

Thomas Weide, PhD
University Hospital of Münster (UKM), Internal Medicine D (MedD), Molecular Nephrology
Albert-Schweitzer-Campus 1 Building A14, 48149 Münster, Germany

Email: weidet@uni-muenster.de
Phone: +49 251 57939
Fax: +49 251 57943

© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Molecular Biology and Evolution. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Abstract
The recent and exclusively in humans and a few other higher primates expressed APOL1 (Apolipoprotein L1) gene is linked to African human trypanosomiasis (also known as African sleeping sickness) as well as to different forms of kidney diseases. Whereas APOL1’s role as a trypanolytic factor is well established, pathobiological mechanisms explaining its cytotoxicity in renal cells remain unclear. In this study, we compared the APOL family members using a combination of evolutionary studies and cell biological experiments to detect unique features causal for APOL1 nephrotoxic effects.

We investigated available primate and mouse genome and transcriptome data to apply comparative phylogenetic and maximum likelihood selection analyses. We suggest that the APOL gene family evolved early in vertebrates and initial splitting occurred in ancestral mammals. Diversification and differentiation of functional domains continued in primates, including developing the two members APOL1 and APOL2. Their close relationship could be diagnosed by sequence similarity and a shared ancestral insertion of an AluY transposable element. Live cell imaging analyzes showed that both expressed proteins show a strong preference to localize at the endoplasmic reticulum (ER). However, glycosylation and secretion assays revealed that – unlike APOL2 – APOL1 membrane insertion or association occurs in different orientations at the ER, with the disease-associated mutants facing either the luminal (cis) or cytoplasmic (trans) side of the ER. The various pools of APOL1 at the ER offer a novel perspective in explaining the broad spectrum of its observed toxic effects.

Introduction
APOL1 (Apolipoprotein L1) is the most-studied variant of six members of conserved human proteins (APOL1-6) and has been identified as a trypanolytic factor by protecting humans against African sleeping sickness causing Trypanosoma parasites (Hajduk et al. 1989; Raper et al. 1999; Vanhamme et al. 2003; Pays et al. 2014; Weckerle et al. 2016). Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense subspecies are resistant to APOL1 and escaped from APOL1 toxicity. By a co-evolutionary arms race, two variants of APOL1 – G1 (S342G/I384M) and G2 (Δ388N, Δ389Y) – re-established the APOL1-linked protection against these parasites in in humans of sub-Saharan African ancestry (Pays et al. 2014; Capewell et al. 2015; Kruzel-Davila, Wasser, et al. 2017). The APOL1 variant G2 lyses Trypanosoma brucei rhodesiense, but not Trypanosoma brucei gambiense, whereas APOL1-G1 is associated
with latent, asymptomatic infections in those infected with *Trypanosoma brucei gambiense* (Cooper et al. 2017).

However, similar to the link between sickle cell anemia and human resistance to malaria, two copies of these variants cause an increased risk for numerous renal, predominantly glomerular, diseases (Freedman et al. 2010; Genovese et al. 2010; Kasembeli et al. 2015). These include HIV- and hypertension-associated nephropathy, focal segmental glomerulosclerosis, lupus nephritis, membranous nephropathy, and - as recently shown - also Covid-19 associated renal failure (Tzur et al. 2010; Kopp et al. 2011; Larsen et al. 2014; Velez et al. 2020). These diseases’ common features include proteinuria and rapidly progressive kidney disease, which often results in end-stage renal disease (Wiggins 2007). Therefore, podocytes – unique postmitotic cells, essential for the glomerular filtration barrier establishment and maintenance – are most likely a primary cellular target for APOL1-associated renal cytotoxicity (Wiggins 2007; Kopp et al. 2020).

All APOL family members share high sequence homology. In a concept initially suggested by *Pays and colleagues* for APOL1 (Perez-Morga et al. 2005; Pays et al. 2006), and extended to all APOL family members by *Smith and Malik*, APOL proteins contain three functional parts: a pore-forming domain (PFD), a membrane addressing domain (MAD), and SRA-interacting-protein-like domain (SID) (Smith and Malik 2009). The PFD of APOLs include Bcl-2 homology 3 (BH3) domain-like sequence motifs (BSMs), that have been linked to anti- or pro-apoptotic features (Wei et al. 2001; Shamas-Din et al. 2011; Dummer et al. 2015; Adams and Cory 2018). A further common feature of the APOL family is that their expression can be induced by inflammatory triggers, *e.g.*, interferons or TNFα, indicating that they are part of the innate immune system (Vanhollebeke and Pays 2006; Zhaorigetu et al. 2008; Liao et al. 2011; Zhaorigetu et al. 2011; Nichols et al. 2014). *APOL1* is only expressed in humans and a few other higher primates. It is the only APOL family member containing an N-terminal signal peptide (SP) mediating its secretion into the serum as a trypanolytic factor (Duchateau et al. 1997; Pays et al. 2006; Friedman and Pollak 2011).

In contrast, numerous studies provide evidence that the increased risk for renal diseases is caused by intracellular and therefore non-circulating pools of APOL1 (Chen et al. 2015; Heneghan et al. 2015; Khatua et al. 2015; Ma et al. 2016; Olabisi et al. 2016; Beckerman et al. 2017; Granado et al. 2017; Kruzel-Davila, Shemer, et al. 2017; Madhavan et al. 2017; Shah et al. 2019; Ma et al. 2020; Uzureau et al. 2020). The observation that reduced kidney allograft
survival is linked to the donor’s and not the recipient’s genotype supports this (Reeves-Daniel et al. 2011; Lee et al. 2012; Freedman et al. 2015; Freedman et al. 2016). Of note, APOL2-6 lack SPs, suggesting that common or evolutionarily conserved properties of APOLs are most likely linked to intracellular functions. Thus, considering evolutionary aspects combined with in silico prediction tools and cell biological experiments may help us obtain more in-depth insights into the pathobiological details of APOL1-associated cell injury.

Results

**APOL1 and APOL2 are the most recent members of a 300 MYA old gene family.**

We reconstructed the genomic locus of the APOL gene family and included for the first time the gene APOLD1 (from Apolipoprotein L domain containing 1), which shows modest homology (~30% identity) to the central part of human APOL6 (BSM and membrane insertion domain/MID) on protein level (Regard et al. 2004). The APOLD1 sequence is highly conserved and shows 88% identity (92% similarity) versus mouse APOLD1 and 62% identity (75% similarity) versus APOLD1 from chicken. It is present in all mammals and can be traced back 300 million years ago (MYA) to an amniote ancestry. The high APOLD1 similarity in deep vertebrate splits indicates strong functional constraints (Fig. 1).

APOL6 and APOL5 are represented in most placental species. However, the mouse genome lacks APOL5. All other investigated APOL gene family members are significantly younger and either primate or rodent-specific (Page et al. 2001; Smith and Malik 2009; Kreit et al. 2015). Our data suggest a rodent-primate APOL6-like ancestor gene origin about 70 MYA (Fig. 1B, supplemental data SD1-3) that – after duplication – diverged independently into numerous APOL genes in man and mouse. Thus, mice (mm: *Mus musculus*) contain twelve APOL genes that can be divided into mmAPOLD1, mmAPOL6, an mmAPOL7 group (mmAPOL7a, 7b, 7c, and 7e), mmAPOL8, an mmAPOL9 group (mmAPOL9a, 9b), and an mmAPOL10/11 group (mmAPOL10a, 10b, 11a, 11b). All these genes are clustered on chromosome 15 except mmAPOLD1, which is located on chromosome 6. The human (hs: *Homo sapiens*) APOLD1 is localized on chromosome 12, and human APOL1-6 genes are clustered on chromosome 22 (Fig. 1, SD1-3, and Smith and Malik 2009).

To verify the protein sequence-based reconstruction and derive some information about splitting times of APOL genes in humans, we aligned the entire genomic sequences of the
human \textit{APOL1-6} cluster and searched for phylogenetically informative transposed elements. These elements were inserted before splitting of different gene members. Therefore, orthologous transposons shared among the various duplicated \textit{APOL} genes reveal their close evolutionary relationships. Furthermore, based on the age of the inserted diagnostic elements and their species distribution, they provide information about the timeframe of duplication and diversification (Kuryshev et al. 2006).

This approach provides an additional perspective on the evolution of \textit{APOL} gene families and resulted in the identification of two phylogenetically diagnostic, primate specific \textit{Alu} SINEs (short interspersed elements) in the human \textit{APOL} gene cluster: \textit{AluJ} and \textit{AluY}. The shared diagnostic \textit{AluJ} element was detected in the intronic region of all investigated primates at orthologous positions in \textit{APOL1-4} and was probably inherited from a common primate ancestor about 70 MYA. Only \textit{APOL1} and \textit{APOL2} shared the diagnostic \textit{AluY} element in the 5’ UTR. The orthologous \textit{AluY} transposon was already present in Catarrhine primates that diverged about 30 MYA (for dating see Churakov et al. 2010). Thus, the common \textit{AluY} motif indicates a close relationship between \textit{APOL2} and \textit{APOL1}.

The \textit{APOL1} splice variants correspond to the terminology suggested by Khatua et al. (2015). Figure 2 presents the cumulated exon composition of \textit{APOL1} isoforms compared to \textit{APOL2-4} and includes the positions of diagnostic \textit{AluJ} and \textit{AluY} insertions which are absent in \textit{APOL6}, \textit{APOL5}, and \textit{APOLD1}. In addition, our studies revealed traces of a MER41G long terminal repeat element in \textit{APOL1-4} genes. They lead to a new alternative transposable element exon (TE exonization) and transcription termination in the \textit{APOL4} gene (Fig. 2, SD4).

\textbf{\textit{APOL1} and \textit{APOL2} show different expression in human organs during development.}

Expression patterns during mammalian organ development may provide first hints about the different functions of closely related \textit{AluY}-positive \textit{APOL1} and \textit{APOL2} genes. In addition, it may give some information on why only \textit{APOL1} is linked to human diseases, once as a protective trypanolytic factor and once as a risk gene for renal diseases. Therefore, we next analyzed the expression patterns of these genes and used a recently established database of developmental transcriptomes of seven organs (cerebrum, cerebellum, liver, heart, kidney, ovary, and testis) across seven species (human, macaque, mouse, rat, rabbit, opossum, and chicken) (Cardoso-Moreira et al. 2019). We only analyzed human transcriptomes of cerebrum, cerebellum, liver, heart, and kidney because they include both, pre- and postnatal
stages. In these organs, APOL1 and APOL2 are predominantly expressed at postnatal stages (Fig. 3). At embryonic and prenatal stages, APOLs exhibit no or only background expression.

APOL1 and APOL2 also appear to exhibit organ-specific expression profiles. In cerebrum and cerebellum, APOL2 is the predominantly expressed APOL gene. This was also observed in other transcriptome databases (SD5). Its expression increases during the lifespan, whereas APOL1 is only poorly expressed. The predominant APOL gene in the liver is APOL1 (Fig. 3, SD5). Its expression is dramatically induced after birth and is maintained at a very high level (~80 RPKM). APOL2 also exhibits robust postnatal expression, but only approximately one-fourth of that of APOL1. In heart, APOL1 and APOL2 expressions are significantly upregulated at postnatal stages. Finally, both genes are highly expressed in the kidney at postnatal stages and 19 weeks post-conception. Together, closely related APOL1 and APOL2 show different organ-specific expression patterns.

**APOL1-APOL2 evolutionary splitting leads to different APOL1 orientations at the ER.**

In contrast to APOL2, APOL1 is expressed in different splice variants (vA, vB1, vB3, and vC; Fig. 2). Therefore, we applied live-cell imaging to determine the intracellular distributions of GFP-tagged APOL1 splice variants and APOL2 in immortalized podocytes (AB8 cell line, Fig. 4), and HEK293T cells (SD6-8). In both cell lines, all GFP-tagged APOL1 and APOL2 proteins predominantly co-localized with the ER live-cell imaging dye (ER Tracker, Fig. 4); only in some cells, a meager fraction of APOL1 could also be detected co-localizing with the plasma membrane (SD6). Thus, binding to ER membranes seemed to be an evolutionarily conserved common feature of APOL1 and APOL2, as GFP-tagged APOL3 and APOL4 showed different intracellular distributions (SD7, SD8).

In contrast to APOL2 (and the other APOLs), APOL1 is the only family member found in the bloodstream, indicating that it is released *via* the secretory pathway. This requires the complete insertion of the nascent APOL1 polypeptide into the ER lumen mediated by a functional signal peptide on a molecular level. We, therefore, wondered if all APOL1 splice variants carry functional SPs or if some variants failed to be secreted and thus remained on the cytoplasmic side of the ER. To address this, we first focused on the different N-terminal regions of APOL1 splice variants that are unique to APOL1 and utterly absent in all other APOLs, including APOL2. *In silico* analyses (SignalP, TMHMM) using the first 60 amino acids of the APOL1 splice variants predicting putative SPs or hydrophobic transmembrane regions
(TM) led to ambiguous results. These predictions identified putative SPs or hydrophobic helices either only in APOL1 vA and vC or only in vA and vB1 (SD9). We, therefore, addressed this aspect experimentally and replaced the endogenous SP of the reporter enzyme SEAP (secreted alkaline phosphatase) by the different N-termini of APOL1 splice variants and the well-known SP of HSA (human serum albumin) as a positive control (Fig. 5A,B). Indeed, the SEAP secretion assays (Fig. 5B, SD9) demonstrated functional SPs in the N-termini of APOL1 vA, vB1, and vC, similar to secretion positive controls (SEAP or HSA SPs). Only SEAP fused to the N-terminus of APOL1 vB3, and the negative control (SEAP without SP) was not secreted. Thus, alternative splicing of APOL1 results in functional SPs of some but not all variants.

APOL2, APOL1 vB3 (Fig. 4), and APOL1 in which the SP was replaced by GFP (Granado et al. 2017), are targeted to the ER. This data suggests that the APOL1 ER targeting is due to structural information, independent of the N-terminal SP. Therefore, we wondered, how ER targeting could be conserved among APOL1 and APOL2 proteins and second, how – in the case of APOL1 – it might be linked to its cytotoxic effects.

In silico analyses using full-length APOL1 (vA), and APOL2 sequences suggest the presence of two to five TMs for APOL1 (including the SP) and two or three TMs for APOL2 (SD10-12). The relative positions of the most significant two TMs within the primary structure are very similar between APOL1 and APOL2 (SD10-12). We addressed the possible orientations of various APOL1 splice variants and APOL2 in the ER to examine whether their SIDs – which in case of APOL1 carries the renal risk variants – faced the luminal (cis) or cytoplasmic side (trans). For that purpose, we took advantage of an artificial N-glycosylation tag (GT, Glyco-tag) (Kaup et al. 2011) that only becomes glycosylated in the ER lumen. We fused this tag to the C-termini of various APOL1 splice variants, APOL2 and included an APOL1 mutant lacking the first 59 amino acids of the N-terminus. This ΔN59 deletion mutant is very similar to APOL2, and even starts with an almost identical amino acid sequence (Fig. 5C). We expressed these GT-tagged APOL proteins in HEK293T cells. Lysates of transfected cells were treated with and without PNGaseF, a glycosidase that completely removes N-glycosylation. A shift on SDS-PAGE when treated with PNGaseF was present only for APOL1 vA, vB1, and vC, demonstrating an N-glycosylation of the C-terminus of these APOL1 splice variants (Fig. 5D). The shift was independent of APOL1 SID variants. Thus, APOL1 G0 and the RRVs G1 and G2 have the same orientation in the ER lumen (Fig. 5E,F and SD13). However, PNGaseF treatment had no effects on GT-tagged APOL1 vB3, APOL1 lacking the complete N-terminus, including the SP (ΔN59),
APOL2 (Fig5C-F), or APOL1 protein in which the SP (aa1-28) was replaced by an N-terminal GFP-tag (SD13). The GT and GFP-tag (GFP-GT) combination fused to APOL1 and APOL2 at the C-terminus led to the same outcomes (Fig 5E,F and SD13). Together, these data align with the SEAP assays and demonstrated a luminal (cis) ER localization of the APOL1 SIDs only in splice variants carrying functional SPs.

Of note, the APOL1 mutant ΔC305-GFP-GT, which contains an SP but lacks the SID, becomes glycosylated (Fig. 5E,F) and localizes to the ER (SD14). Furthermore, we also observed a luminal orientation and ER localization for a C-terminally GFP-GT-tagged APOL1 with an APOL2-BSM, and an APOL1-APOL2 chimera carrying the APOL1 SP, the APOL2 PFD and MAD, and the APOL1 SID (SD14 and SD15). Thus, our data show that APOL1 can be expressed in two different orientations at the ER, one fraction (vA, vB1, and vC) with the SID localized inside the ER lumen (cis) and one (vB3) with the SID facing the cytoplasm (trans), like APOL2.

**APOL1 shows cytotoxic effects in both orientations.**

We determined the cytotoxic potential of cis- and trans-orientated APOL1 (G0 and RRVs). Both, APOL1-GFP which have luminal orientated SIDs as well as GFP-APOL1 (in which the SP was exchanged by GFP), showed reduced cell viability after 24 and 48 hours (Fig. 6). The reduced cell viability was pronounced with APOL1 renal risk variants (G1 and G2) but was also present with the used African APOL1 G0 haplotype (E150/I228/K255, see Lannon et al. 2019 and SD16). In contrast, APOL2 overexpression had no toxic effect (Fig. 6).

Since GFP-APOL2 showed the same trans ER orientation as GFP-APOL1 (with the toxic RRV G2), we also investigated the BSM roles in trans-orientated APOL1 cytotoxicity (and APOL2 non-toxicity). To address this, we modified the APOL1 BSM (NIRRLRALADGVQKV) by mutating its LRAD core sequence into six alanine residues (NIRRAAAAAAGVQKV; called B_{6xAla}) or by changing the BSM of APOL1 into that of APOL2 (HIRKLRALAEVEQV; B_{2}). Strikingly, both modifications led to a loss of APOL1 cytotoxicity (Fig. 6B), demonstrating that APOL1 cytotoxicity in trans orientation requires the BSM. In addition, APOL1 with the APOL2 BSM maintained its ER membrane targeting, whereas APOL1 with the B_{6xAla} sequence showed a cytoplasmic localization (SD15). Chimeric APOL2 proteins, carrying the toxic SID of APOL1-G2 (P_{2}M_{2}S_{1}-G2) or both, the putative pro-apoptotic APOL1 BSM and toxic SID (P_{2}B_{1}M_{2}S_{1}-G2), were unable to cause toxic effects (data not shown). Thus, cytotoxicity is unique to APOL1, present for both ER orientations but not transferable to cytoplasmic orientated APOL2.
Positively selected sites of APOL1 are localized in putative transmembrane regions.

Previous work is suggesting that APOL1-linked cytotoxicity mainly bases on cation channel activity at the plasma membrane (Thomson and Finkelstein 2015; Olabisi et al. 2016; Bruno et al. 2017; Giovinazzo et al. 2020; Schaub et al. 2020). This results in novel topology conceptions for APOL1, in which the SP is followed by up to four additional transmembrane regions (Giovinazzo et al. 2020; Gupta et al. 2020; Scales et al. 2020; Schaub et al. 2020).

Therefore, we reevaluated codons that are under positive selection during APOL1 evolution. These analyses were performed in PAML (Yang 2007) and based on a codon alignment of exon 6 and exon 7 (APOL1 vA equivalents for APOL2-4, SD17). By applying site-specific models M2 (selection) versus M1 (neutral) and M8 (selection) versus M7 (neutral), and a branch-site model (labeled 2201), more than 100 potential amino acid sites under positive selection were identified (SD17). We selected 27 of them with significant support from at least two investigated models and arranged them with the previously detected positively selected sites (Fig. 7A). Three of the 27 twice supported sites (Y273, E313, Y351) correspond to positively selection positions previously identified by Smith and Malik (2009). Relaxing the stringency to once significantly detected sites (M2, M8, or 2201) revealed an overlap of 17 of the 23 positively selected sites of Smith and Malik (Fig. 7A, SD17). Strikingly, 15 of the 27 positive selected sites are within or close to two putative TMs (TM3: aa257-276 and TM4: aa 332-353, Fig. 7, SD17 and SD18).

Discussion

Our evolutionary tree reconstructions elucidate an ancestral APOLD1-like precursor gene as the origin of the entire gene family. In addition, our data show almost entirely independent divergences of the APOL gene families in mouse and human, leading to six further human and twelve murine APOL genes (Fig. 1, SD1-3, and Page et al. 2001; Smith and Malik 2009; Kreit et al. 2015). A search for phylogenetically diagnostic primate-specific transposable elements revealed two Alu SINEs in the APOL gene family. AluI is located at orthologous positions in APOL1-4, and AluY exclusively is shared by APOL1 and APOL2 genes. The sequence-based tree reconstruction argues for a common human-mouse APOL6-like ancestor gene 70 MYA that later diverged into the AluI-orthologous APOL1-4 genes in all investigated primates, followed by the appearance of AluY-orthologous APOL1-2 genes in Old World monkeys (Catarrhini). APOL5 is among the placental precursors of APOL genes but removed from the mouse
genome. **APOLD1**, on the other hand, predates the mammalian divergence and is still highly conserved in most vertebrates. Whereas **APOL2** is found mainly in the brain, the highest expression of **APOL1** is in the liver indicating that divergences of **APOL** genes are linked to organ-specific expression patterns and cell type-specific roles of the various family members. The high expression level of **APOL1** in the liver (Shukha et al. 2017) is remarkable as the liver is the chief secretory organ, releasing many if not most of the blood serum components, including **APOL1** (wildtype) and **HPR** (Haptoglobin-related protein), which are key components of the trypanolytic factor (TLF) that confers innate resistance to all strains of *Trypanosoma brucei*, except for subspecies *Trypanosoma brucei rhodesiense* and *Trypanosoma brucei gambiense* (Genovese et al. 2010; Harrington et al. 2014; Cooper et al. 2017; Shukha et al. 2017; De Simone et al. 2020).

In contrast to their different organ-specific expression pattern, which is most likely due to tissue-specific promotor activities, **APOL1** and **APOL2** mainly localize to the ER on an intracellular level. Taking advantage of live cell imaging approaches using GFP-tags our data suggest that ER targeting is a common and, therefore, probably evolutionarily conserved feature of these closely related proteins. However, this raises the question how the common intracellular localization of these proteins is linked to their opposite cytotoxic properties.

The SEAP secretion and Glyco-tag assays used in this study demonstrated that **APOL1** variants vA, vB1, and vC are located inside the ER (*cis*), whereas those of vB3 and **APOL2** are faced to the cytoplasmic (*trans*) side of the ER. In this context it is worth noting that the SEAP and glycosylation assays are strongly in line with the **APOL1** splice variant orientations elucidated by Scales and colleagues using differential permeabilization assays in combination with numerous highly specific antibodies (Scales et al. 2020). Thus, evolutionary splitting into **APOL1** and **APOL2** genes resulted in different ER membranes orientations, but only for three-fourths of the **APOL1** splice variants (vA, vB1, and vC). This is of substantial relevance for the various discussed **APOL1** pathomechanisms, as it is still discussed whether circulating (meaning secreted) (Hayek et al. 2017) or rather intracellular fractions (in *cis* or *trans* orientation) cause **APOL1**-linked renal diseases (Bruggeman et al. 2014; Cheng et al. 2015; Heneghan et al. 2015; Khatua et al. 2015; Lan et al. 2015; Ma et al. 2016; Olabisi et al. 2016; Beckerman et al. 2017; Granado et al. 2017; Kruzel-Davila, Shemer, et al. 2017; Madhavan et al. 2017; Shah et al. 2019; Ma et al. 2020; Uzureau et al. 2020).
In a scenario in which APOL1 cytotoxicity requires the SID facing the cytoplasm (Fig. 7B, SD18) only cytoplasmic APOL1 vB3 – or non-processed and therefore non-membrane integrated APOL1 pools – fulfill this criterion. This is in line with studies in which APOL1-cytotoxicity was linked to APOL1 targeting to the outer mitochondrial membrane (Ma et al. 2016), the mitochondrial transition pores (Shah et al. 2019), mitochondrial fission (Ma et al. 2020), or to interactions with Vamp8 (Madhavan et al. 2017) and APOL3 (Uzureau et al. 2020). Moreover, recently Wakashin et al. identified the intracellular NLRP12 (NLR family pyrin domain containing 12) – a key regulator of Toll-like receptor signaling – as a binding partner of the APOL1 vB3 variant. The data suggest a role in which APOL1 vB3 triggers an enhanced podocyte damaging by an upregulated inflammatory signaling (Wakashin et al. 2020).

Trans orientated APOL1 also fits the observation that it can bind to phosphoinositides, which are present on the ER’s cytoplasmic leaflet (Wan et al. 2008; Chun et al. 2019). Together this indicates that SP-less APOL1 vB3, as well as APOL2 most likely bind peripherally to these lipids (Fig. 7B).

The identified BH3-only like sequence motif of APOL proteins points to a similar role in cell programmed death (PCD) scenarios as shown for other members of the Bcl2-family (Vanhollebeke and Pays 2006; Wan et al. 2008; Smith and Malik 2009). Some members have been identified as factors mediating PCD by directly activating Bax/Bak proteins at the outer mitochondrial membrane to trigger apoptosis (Shamas-Din et al. 2011; Dummer et al. 2015; Adams and Cory 2018). Intriguingly, cytoplasmic orientated GFP-APOL1 in which its BSM is replaced by that of APOL2 loses its cytotoxicity (while maintaining ER targeting; Fig. 6B, SD15). This data suggests a BSM role as co-factor in APOL1-linked cell death (Wan et al. 2008; Lan et al. 2015) and is in line with previous studies that observed mitochondrial damaging in cells overexpressing APOL1 (Ma et al. 2016; Shah et al. 2019).

Our data elucidated functional SPs for APOL1 vA, vB1 and vC and, therefore, a luminal orientation of these splice variants’ C-termini. Strikingly, such a cis orientation agrees with scenarios in which APOL1’s cytotoxic effects are caused by ion channel activity at the plasma membrane (Thomson and Finkelstein 2015; Olabisi et al. 2016; Bruno et al. 2017; Giovinazzo et al. 2020; Schaub et al. 2020), or where APOL1 is acting as a paracrine (meaning secreted) factor (Hayek et al. 2017).

The ΔC305-GFP-GT mutant, which lacks the APOL1 SID but contains the SP of variant A and the helix-turn-helix loop of the MID (aa 177-228) showed a luminal orientation. This data
indicates the presence of a central membrane insertion domain composed of two juxtaposed membrane spanning helices (TM1 and TM2) and suggests that – at least in this mutant – the region between aa 257-276 is unable to form a third membrane spanning helix (TM3). From this point of view, the ΔC305 mutant supports a current topology concept in which APOL1 – in addition to the SP – contains two TMs and a “half-spanning loop” (Fig. 7 and Gupta et al. 2020).

In an alternative concept, APOL1 forms an active cation channel by four TMs, including the central membrane insertion domain (MID, aa 177-228, TM1 and TM2), a pore-lining region (PLR, aa335-356, or TM4), and an additional TM3 between MID and PLR (aa 257-276, see Fig. 7 and Giovinazzo et al. 2020; Schaub et al. 2020). In this model, changes of the intracellular pH-values appear to be crucial for APOL1 membrane insertion and channel function. This includes the possibility that proper formation of a third TM may require the C-terminal SID (aa305-398), indicating that only the full-length APOL1 vA can form four TMs. However, in every case, the suggested APOL1 topology concepts are in line with our glycosylation (and secretion) assays. Most positively selected sites during APOL1 evolution are close to or even within the novel postulated TM3 and TM4 (Fig.7A, SD16). Remarkably, positively selected sites also include Y351. This tyrosine is crucial for the pH-dependent gating of APOL1-linked ion channel activity (Schaub et al. 2020) or part of a putative half-spanning loop, suggested by Gupta et al. (2020).

The different APOL1-pathomechanisms are finally a consequence of alternative splicing of the APOL1 gene. Indeed, alternatively spliced transcripts of a gene can regulate various biological processes, and their evolution often led to functional innovation (Bush et al. 2017). Interestingly, the start codon and 5' GT splicing site of alternative exon 2 of APOL1 (APOL1 vB1; Fig. 2A) that constitute one of the two signal peptide initiation codes of APOL1, is present in most primate species representatives of APOL1-4 genes (SD4), but the expression is restricted to APOL1. Apart from that, the alternative signal peptide from exon 3 of APOL1 (APOL1 vA and APOL1 vC) is also represented and expressed for APOL4 (Fig. 2A-B; SD4). In this context, it is worth mentioning that the rapid evolution of signal peptides correlates to a relaxed selection on non-synonymous and synonymous sites in a gene (Li et al. 2009). Thus, gene duplication goes ahead with relaxation from selective constraints and may explain the evolution of the signal peptides of APOL1 after divergence from APOL2. Therefore, it is
tempting to speculate that the ratio between APOL1 splice variants is part of ongoing evolution.

Under normal conditions, high and efficient APOL1 secretion may result in low levels of non-processed, luminal-faced fractions of APOL1 at the ER, thereby most likely preventing damaging of the secreting cells. However, an upregulation of APOL1, triggered by inflammatory cytokines, may cause an overload of APOL1 pools at the ER in cis and trans orientation (Nichols et al. 2014). Thus, ER targeting combined with high expression levels at the ER could be a key determinant in APOL1-linked cytotoxicity, particularly in postmitotic cells like podocytes with a very limited self-renewal capacity (Wen et al. 2018).

Recent studies elucidated high APOL1 expression levels as an essential co-factor for APOL1-linked cytotoxicity (O’Toole et al. 2018; Datta et al. 2020). Furthermore, increasing evidence identified ER stress per se as an aggravating or disease-promoting factor for podocyte diseases (Cybulsky 2013; Cybulsky 2017). Thus, APOL1 pools at the ER combined with their potential to cause ER-linked disturbances might have - as yet - underestimated potentials in explaining why SP-lacking as well as SP-containing APOL1 (especially of the G1 and G2 RRVs) induce the observed pleiotropic toxic effects in in vitro and in vivo models.

APOL1’s pathobiological mechanisms explaining its cytotoxicity in renal cells are still controversially discussed. This study focusses on the evolutionary history of the APOL gene family in mouse and human. In addition, it provides experimental data that both cis (luminal) as well as trans (cytoplasmic) orientation of APOL1 splice isoforms could be responsible for the wide spectrum of pathogenic mechanisms proposed for podocyte damage leading to kidney disease. However, APOL1-linked cytotoxicity depends on many factors, including APOL1 expression levels, the haplotype, the presence of renal risk variants, its intracellular localization, and most likely also on the ratio between cis and trans orientated APOL1 pools. Hence, further studies will be necessary to address how a renal risk is turned into APOL1-linked kidney diseases.

Author contributions
D.M. performed most of the experiments, supported by K.F., D.G., A.C.G., V.K., S.M.L., and T.M.A. Evolutionary studies were mainly done by J.S. D.M., K.F., A.C.G., J.S., and T.W. analyzed the data. D.M., H.P., and T.W. designed the study. D.M., J.S., and T.W. prepared the manuscript. All authors approved the final manuscript.
Acknowledgements

We thank Beate Surmann, Truc Van Le, and Kristin Doctor for excellent technical support, all laboratory members for fruitful discussions, and Dr. Gia Voeltz for plasmids. Moreover, we thank Dr. Beate Vollenbröker and Dr. Daniela Braun for the critical reading of the manuscript. Finally, we thank the members of EvoPAD for the inspiring discussions of APOL evolution. The work was supported by grants from the German Research Foundation to T.W. (grant number DFG WE 2550/3-1) and J.S. (grant number DFG SCHM 1469/10-1). K.F and T.M.A. were supported by the Medical Faculty of the University of Muenster (grant numbers MedK No. 18-0022 and No. 16-0087, respectively). The work contains parts of the PhD thesis of D.M. and the MD theses of K.F. and T.M.A..

Disclosures

None.

CONSISE METHODS

Phylogenetic tree and gene reconstruction

We extracted all known human and mouse APOL genes using the UCSC Gene Sorter (https://genome.ucsc.edu). The APOL gene family’s gene architecture was derived from both species following the graphically visualized genome assemblies of the UCSC Genome Browser (Fig. 1A). To reconstruct the evolutionary history of APOL genes, we assembled all amino acid sequences from the large homologous exon 7 (corresponding to APOL1 vA; Fig. 2A) in PhyDE (http://www.phyde.de). The alignment was optimized using the MUSCLE multiple sequence aligner PhyDE plugin (Edgar 2004). SplitsTree4 (version 4.15.1, Huson and Bryant 2006) was used to reconstruct the phylogenetic tree of APOL genes. We used the Character Method ProteinMLdist under the JTT reconstruction model and 4 gamma categories to derive the gene affiliations shown in Fig. 1. SplitsTree reconstructs a consensus network that visualizes potential data conflicts by parallelograms. Next, we performed a bootstrap analysis of a random subset of the data with 100 replicates. When 100% of the resampled datasets showed the same split (suggesting solid phylogenetic signals in the original data set), the related branch was labeled with 100 in the consensus network. The tree topology was verified by applying a maximum likelihood analysis in MEGA7 (JTT matrix-based model, discrete Gamma distribution applying 4 gamma categories, 100 bootstrap replications), and applying a
Detecting clade-supporting insertions of transposable elements

To obtain additional information about the relationship and age of different \textit{APOL} genes in humans, we extracted intron, exon, and UTR genomic regions of the human \textit{APOL} genes. To detect diagnostic TE insertions shared among the primate \textit{APOL} genes, we aligned all six \textit{APOL} genes from various primate representatives (human, orangutan, rhesus monkey, baboon, squirrel monkey, mouse lemur). To identify transposed elements, we ran a local RepeatMasking (www.repeatmasker.org). We extracted \textit{Alu} SINEs, which were then inspected for insertion homology using a genomic alignment from the different members of the \textit{APOL} gene family (SD4). Such diagnostic elements are inserted before splitting various gene members, and after that, they represent informative presence/absence markers of relationship at their homologous gene positions. \textit{Alu} SINEs are primate-specific and the most abundant transposed elements in primates, thus uniquely suitable as clade markers to analyze genes and species' evolution (Churakov et al. 2010). Comparative analyzes of the presence/absence patterns of the identified TEs in various primate species enabled us to determine their evolutionary time of insertion.

Detecting positive selection sites

To detect positively selected sites within protein-coding sequences, we (1) used the PAML site specific model (model = 0, NSsites = 0 1 2 7 8) and a single Newick user tree, and (2) the branch-site model (Model = 2, NSsites = 2, \( \omega = 0 \) (estimated), initial \( \omega = 1 \) labelled 2201 vs. \( \omega = 1 \) (predetermined neutral), initial \( \omega = 1 \) labelled 2211) (SD16). The PAML incorporated Bayes Empirical Bayes analysis determined the probability of positive selection for each codon position (Fig. 7).

Constructs and cloning

Expression cassettes encoding EGFP-\textit{APOL}1 G0 lacking the SP (EGFP-\textit{ASP} \textit{APOL}1, aa 28-398), or encoding full-length \textit{APOL}1 G0 with a C-terminal EGFP-tag have been described earlier (Granado et al. 2017). Standard site-directed mutagenesis was used to obtain cDNAs encoding for \textit{APOL}1 G1 (S342G/I384M) and G2 (\( \Delta 388N389Y \)) renal risk variants. Human \textit{APOL}2, \textit{APOL}3, and \textit{APOL}4 cDNAs were cloned using a human cDNA library derived from AB8 podocytes (Duning et al. 2008) and cloned into pEGFP-N1 (BD Clontech), a modified pEGFP-C2
(encoding RFP instead of EGFP), or pENTR-vectors according to the manufacturer’s instructions (Thermo Fisher Scientific). For glycosylation analysis, a Glycotag-tag1.4 tail (AAAAAANATVAAASGDVWDI) (Kaup et al. 2011) was fused to the C-terminal part of different APOL constructs via PCR. Furthermore, APOL2-APOL1 chimeric constructs, as well as APOL1/2 BH3 mutants, were generated using overlapping primers combined with in combination with SOE PCR techniques. All APOL constructs, deletion constructs, mutants, Glyco- variants, and chimeric constructs were cloned into pENTR or pENTR-EGFP vectors and shuttled into a modified pINDUCER21-Puro destination vector as previously described (Schulze et al. 2014). The pSEAP2-Control vector from Clontech (Takara Cat No # 631717) served as a template for the different SEAP APOL1 splice variant constructs. For the N-termini, different primers were designed whereby the different APOL1 N-termini and the HSA SP were fused to SEAP during PCR, or the SP of SEAP was deleted (SEAP, SEAPΔSP, SEAP-vA-cSPlcs, SEAP-vC-cSPlcs, SEAP-HSA-SP). Via restriction cloning, the amplified DNA was ligated into a Gateway™ pDONR™221 vector (Invitrogen Cat # 12536017) and labeled as pENTR after insertion. For APOL1vB1 the pENTR-SEAP-APOL1vA, and for APOL1vB3 the pENTR-SEAP-APOL1vC, constructs served as templates for PCR. The DNA was subsequently cloned into a pENTR-pDONOR via restriction cloning. All SEAP constructs were shuttled in a doxycycline-inducible pInducer21-Puro destination vector (Schulze et al. 2014). pME-mTagBFP-CAAX was a gift from Nicholas Cole (addgene # 75149; Don et al. 2017). The BFP-CAAX cassette was shuttled into a pQCXIH destination vector via Gateway® LR reaction. The mCherry-Sec61β construct (addgene #49155) was kindly provided by Gia Voeltz (Zurek et al. 2011). All constructs were verified by DNA sequencing. Details concerning constructs are summarized in SD19. Primer sequences are available from DM and TW.

Cell lines and transient transfection
HEK293T cells were cultured in standard DMEM medium (Thermo Fisher Scientific) containing 10% FCS and 1% antibiotics and L-glutamine (penicillin/streptomycin) at 37°C under a 5% CO2 atmosphere. Human immortalized AB8/13 podocytes (Saleem et al. 2002) were cultured in standard RPMI 1640 medium (Sigma-Aldrich) containing 10% FCS, 1% supplements, and 1% antibiotics (penicillin/streptomycin) at 33°C under 5% CO2 atmosphere (Schulze et al. 2017). Transient transfections were performed via calcium-phosphate-based precipitation (Schulze...
et al. 2014), or via Lipofectamine 2000 as described in the manufacturer’s specifications (Thermo Fisher Scientific).

**Generation of stable cell lines**
Stable cell lines were generated as previously described (Schulze et al. 2014; Wennmann et al. 2014). Briefly, lentivirus production was performed in HEK293T cells transiently transfected with psPAX2 and pMD2.G helper plasmids and modified pInducer21-Puro-plasmids (Meerbrey et al. 2011) encoding the APOL proteins. The virus-containing supernatant was collected and filtered through a 0.45-µm sterile filter (EMD Millipore). The virus-containing medium was added to HEK293T and AB8 podocyte cells using one volume of fresh DMEM medium and one volume of the virus-containing filtrate supplemented with polybrene (final concentration 8 µg/ml). After 24 hours, the virus-containing medium was replaced by fresh medium, and cells were regenerated for a further 24 hours. Transduced cells were selected using puromycin (4 µg/ml, HEK293T; 2 µg/ml, AB8). All established stable cell lines were tested for inducible overexpression of APOL proteins by western blot and immunofluorescence analysis.

**Cell viability assays**
Real-time cell viability measurements were performed via the RealTime-Glo MT Cell Viability Assay (Promega) according to the manufacturer’s instructions. Briefly, 10,000 HEK293T cells in 50 µl medium were seeded onto 96-well white bottom plates (Nunc). After adherence, 50 µl 2× RealTime-Glo enzyme-substrate mix diluted in medium was added to each well either with or without 125 ng/ml doxycycline (Granado et al. 2017). The luminescence was measured using a 37°C prewarmed microplate reader (TECAN) at the indicated time points. For each cell line, three independent experiments (N=3), including three technical replicates for each N (n=3), were measured.

**Western blot analyses**
Western blot analyses were performed as previously described (Schulze et al. 2014; Schulze et al. 2017). Briefly, cell lysates were boiled for 5 min, and equal volumes were separated via SDS-PAGE using 8% - 15% gels (Bio-Rad). Separated proteins were then transferred to a PVDF membrane (EMD Millipore) and incubated in blocking buffer (5% skim milk powder dissolved in TBS containing 0.05% Tween-20 [TBS-T]) for 1 hour at room temperature (RT). The
monoclonal GFP antibody (JL-8; #632380) was provided by Takara Bio Europe (Clontech). The antibodies against APOL1 (HPA018885), APOL2 (HPA001078), and β-Tubulin (#T8328) were purchased from Sigma-Aldrich, the antibody against α-Actinin 4 (#ALX-210–356) was from Enzo/Alexis. Primary antibodies were used 1:1000 in TBS-T with 5% BSA and incubated at 4°C overnight. The membrane was then washed three times with TBS-T and incubated with horseradish peroxidase-coupled secondary antibodies (Jackson Immunoresearch) diluted 1:3000 in blocking buffer for 30-45 min at RT. After three further wash steps with TBS-T, the signal was detected using the Lumi-Light chemiluminescence detection reagent (Roche).

**Live Cell Imaging and microscopy**

For live-cell imaging, cells expressing fluorophore-coupled APOL fusion proteins were grown on μ-dishes (Ibidi). Labeling of cells with live-cell imaging dyes, ER-Tracker Red Dye (Ex 587 nm/Em 615 nm; #E34250) or MitoTracker Red CMXRos (Ex 579 nm/Em 599 nm; #M7512), was performed according to the manufacturer’s specifications (Thermo Fisher Scientific).

Imaging was performed using an Observer Z1 microscope with APOtome 2.0, Axiocam MRm (Zeiss), and EC Plan APOChromat 63×/1.40 Oil M27, or EC Plan-Neofluar 40×/1.30 Oil DIC M27 objectives, respectively. Alexa Fluor® 594-stained proteins and GFP-tagged fusion proteins were detected using the 38 HE EGFP shift-free filter set (Zeiss). Alexa Fluor®647-stained proteins and red live-cell imaging dyes were imaged using the 43 HE Cy3 shift-free (Zeiss) or 64 HE mPlum shift-free (Zeiss) filter sets. BFP-CAAX was imaged using the 49 DAPI shift-free Filter (Zeiss). APOtome images were merged using the Fourier filter. Image files in ZVI or CZI format (Zeiss Axiovision software 4.8; Zeiss ZEN 2.3; blue edition) were further processed using ImageJ (http://imagej.nih.gov/ij/). For improved visualization of cellular structures, images were smoothed and sharpened using a Gauss Filter (Radius=1) and the unsharp mask filter (Radius=1; Mask Weight 0.6–0.8). Finally, images were contrast-adjusted and mounted to complex figures using CorelDRAW Graphics suite x6 software (Adobe).

**In silico analyses**

Alignment of APOL1 (variant A; 398aa; uniprot O14791) and APOL2 (337aa, uniprot Q9BQE5) sequences was performed using the Multalin software (http://multalin.toulouse.inra.fr/multalin)(Corpet 1988). Amino acid comparison between
APOL1 and APOL2 was observed via protein BLAST (National Center for Biotechnology Information, U.S. National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA). Prediction of putative transmembrane regions was realized by the TMHMM server 2.0 (DTU Bioinformatics; http://www.cbs.dtu.dk/services/TMHMM/TMHMM2.0b.guide.php) (Sonnhammer et al. 1998; Krogh et al. 2001). The SignalP 5.0 server was used to observe putative signal peptides (Almagro Armenteros et al. 2019). APOL gene expression patterns in human organs were analyzed using a database and an evo-devo application tool (https://apps.kaessmannlab.org/evodevoapp) recently provided by Cardoso-Moreira et al. (2019).

Colocalization Analysis

Analysis was performed by using ImageJ. To analyze colocalization between APOL1-EGFP or EGFP-APOL1 and the membrane, labelled with pQXCIH-BFP-CAAX, a mask Image was created. Therefore, the blue channel was duplicated; a threshold called Moments was applied and manually adjusted to remove the background signal. The Coloc2 PlugIn was used to measure the Pearson Correlation Coefficient (PSF 3.0; Pearson’s R-value (no threshold). GraphPad PRISM software was used to visualize the correlation coefficient analysis. Pearson R values $\leq 0.4$ were considered as weak or no correlation, $> 0.4$ until $< 0.7$ moderate correlation and $\geq 0.7$ strong correlation.

Statistical Analyses

Statistical analyses were performed using GraphPad PRISM software. To test if the datasets showed a Gaussian distribution, Shapiro-Wilk normality test was performed. Two groups of normally distributed values were compared using an unpaired $t$-test; two groups of not normally distributed values were compared using a Mann-Whitney. All datasets were pooled from at least three independent experiments. P values of less than 0.05 were regarded as statistically significant.

SEAP assay

To analyze the functionality of different APOL1 N-termini, the secretion of the secreted alkaline phosphatase (SEAP) reporter enzyme was measured. HEK 293 T cells were seeded to
the same confluence onto 6-well plates and transiently transfected with different SEAP gene variants in a pInducer21-Puro system. The pSEAP2-Control vector from Clontech (Takara Cat # 631717) was transfected as a positive control. After transfection, cells were induced with doxycycline (125 ng/ml) and incubated for 48 hours. Media of cell cultures were taken to measure secreted proteins, and the cells were used to perform western blot analysis. For the measurement, 50 µl of vortexed media were added to 250 µl of SEAP working solution (36 µM 4-Methylumbelliferyl phosphate in 50 mM Tris/0.1% BSA buffer, pH 8.0) in a transparent 96-well plate. After two min of incubation in the dark, fluorescence was measured in a microplate reader (Infinite M200, Tecan Group Ltd.) for 60 min. For each cell line, three independent experiments (N=3), including three technical replicates for each N (n=3), were measured.

**RIPA lysates**

Cells were grown on cell culture plates and washed with cold PBS. For cell lysis, cells were transferred on ice and scraped into RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS) containing complete protease inhibitor (Roche) and Phosphatase Inhibitor Cocktail II and III (Abcam). Cells were homogenized by shearing force and then sonicated for 10 min. After removing cell debris and nuclei via centrifugation for 15 min at 4°C and 10,000 g, supernatants were stored at -20°C or directly used for PNGaseF digestion.

**PNGaseF digestion**

The membrane orientations of APOls were elucidated via glycosylation signals of their C-terminal GT-tag. To confirm glycosylation, RIPA lysates were digested with PNGaseF according to the manufacturer’s instructions (New England Biolabs). Laemmli buffer was added to the lysates, and for a digestion control, the origin lysate was mixed with an equal volume of a 50:50 mixture of Laemmli buffer and water.
References

Adams JM, Cory S. 2018. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. *Cell Death Differ.* 25:27–36.

Beckerman P, Bi-Karchin J, Park ASD, Qiu C, Dummer PD, Soomro I, Boustany-Kari CM, Pullen SS, Miner JH, Hu C- AA, et al. 2017. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. *Nat. Med.* 23:429–438.

Bruggeman L a, O’Toole JF, Ross MD, Madhavan SM, Smurzynski M, Wu K, Bosch RJ, Gupta S, Pollak MR, Sedor JR, et al. 2014. Plasma apolipoprotein L1 levels do not correlate with CKD. *J. Am. Soc. Nephrol.* 25:634–644.

Bruno J, Pozzi N, Oliva J, Edwards JC. 2017. Apolipoprotein L1 confers pH-switchable ion permeability to phospholipid vesicles. *J. Biol. Chem.* 292:18344–18353.

Bushman SJ, Chen L, Tovar-Corona JM, Urrutia AO. 2017. Alternative splicing and the evolution of phenotypic novelty. *Philos. Trans. R. Soc. B Biol. Sci.*

Capewell P, Cooper A, Clucas C, Weir W, MacLeod A. 2015. A co-evolutionary arms race: Trypanosomes shaping the human genome, humans shaping the trypanosome genome. *Parasitology.*

Cardoso-Moreira M, Halbert J, Valloton D, Velten B, Chen C, Shao Y, Liechti A, Ascenção K, Rimmel C, Ovchinnikova S, et al. 2019. Gene expression across mammalian organ development. *Nature.*

Chen TK, Choi MJ, Yao L, Zhu X, Murea M, Freedman BJ, Parks JS, Shelnaz GS. 2015. Biogenesis and cytotoxicity of APOL1 renal risk variant proteins in hepatocytes and hepatoma cells. *J. Lipid Res.* 56:1583–1593.

Chun J, Zhang JY, Wilkins MS, Subramanian B, Riella C, Magranner JM, Alper SL, Friedman DJ, Pollak MR. 2019. Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity. *Proc. Natl. Acad. Sci. U. S. A.*

Churakov G, Grundmann N, Kuritzin A, Brosius J, Makaowski W, Schmitz J. 2010. A novel web application and the chronology of the Primate Alu retroposon activity. *BMC Evol. Biol.*

Cooper A, Liboudou H, Albou VP, Ravel S, Enyaru J, Weir W, Noyes H, Capewell P, Camara M, Milet J, et al. 2017. APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis. *Elife.*

Cybulsky A V. 2013. The intersecting roles of endoplasmic reticulum stress, ubiquitin-proteasome system, and autophagy in the pathogenesis of proteinuric kidney disease. *Kidney Int.*

Cybulsky A V. 2017. Endoplasmic reticulum stress, the unfolded protein response and autophagy in kidney diseases. *Nat. Rev. Nephrol.*

Datta S, Kataria R, Zhang JY, Moore S, Petitpas K, Mohamed A, Zahner N, Pollak MR, Olabisi OA. 2020. Kidney Disease-Associated APOL1 Variants Have Dose-Dependent, Dominant Toxic Gain-of-Function. *J. Am. Soc. Nephrol.*

Don EH, Formella I, Badrock AP, Hall TE, Morsch M, Hortle E, Hogan A, Chow S, Gwee SSL, Stoddart JJ, et al. 2017. A Tol2 Gateway-Compatible Toolbox for the Study of the Nervous System and Neurodegenerative Disease. *Zebrafish.*

Duchateau PN, Pullinger CR, Orellana RE, Kunitake ST, Naya-Vigne J, O’Connor PM, Malloy MJ, Kane JP. 1997. Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. *J. Biol. Chem.* 272:25576–25582.

Dummer PD, Limou S, Rosenberg AZ, Heymann J, Nelson G, Winkler CA, Kopp JB. 2015. APOL1 Kidney Disease Risk Variants: An Evolving Landscape. *Semin. Nephrol.* 35:222–236.

Dunifang S, Schurek E-M, Schlüter M, Bayer M, Reinhardt H-C, Schwab A, Schaefer L, Benzing T, Schermer B, Saleem MA, et al. 2008. KIBRA modulates directional migration of podocytes. *J. Am. Soc. Nephrol.*

Freedman BI, Julian BA, Pastan SO, Israni AK, Schladt D, Gautreaux MD, Hautpfeld V, Bray RA, Gebel HM, Kirk AD, et al. 2015. Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure. *Am. J. Transplant.* 15:1615–1622.

Freedman BI, Kopp JB, Langefeld CD, Genovese G, Friedman DJ, Nelson GW, Winkler CA, Bowden DW, Pollak MR. 2010. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. *J. Am. Soc. Nephrol.* 21:1422–1426.

Freedman BI, Pastan SO, Israni AK, Schladt D, Julian BA, Gautreaux MD, Hautpfeld V, Bray RA, Gebel HM, Kirk AD, et al. 2016. APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors. *Transplantation* 100:194–202.
allograft survival. *Am. J. Transplant.* 12:1924–1928.

Li YD, Xie ZY, Du YL, Zhou Z, Mao XM, Lv LX, Li YQ. 2009. The rapid evolution of signal peptides is mainly caused by relaxed selection on non-synonymous and synonymous sites. *Gene.*

Liao W, Goh FY, Betts RJ, Kemeny DM, Tam J, Bay B-H, Wong WSF. 2011. A novel anti-apoptotic role for apolipoprotein L2 in IFN-γ-induced cytotoxicity in human bronchial epithelial cells. *J. Cell. Physiol.* 226:397–406.

Ma L, Ainsworth HC, Snipes JA, Murea M, Choi YA, Langefeld CD, Parks JS, Bharadwaj MS, Chou JW, Hemal AK, et al. 2020. APOL1 Kidney-Risk Variants Induce Mitochondrial Fission. *Kidney Int. Reports.*

Ma L, Chou JW, Snipes JA, Bharadwaj MS, Craddock AL, Cheng D, Weckerle A, Petrovic S, Hicks PJ, Hemal AK, et al. 2016. APOL1 Renal-Risk Variants Induce Mitochondrial Dysfunction. *J. Am. Soc. Nephrol.*

Madhavan SM, O’Toole JF, Konieczkowski M, Barisoni L, Thomas DB, Ganesan S, Bruggeman LA, Buck M, Sedor JR. 2017. APOL1 variants change C-terminal conformational dynamics and binding to SNARE protein VAMP8. *JCI insight.*

Meerbrey KL, Hu G, Kessler JD, Roarty K, Li MZ, Fang JE, Herschkowitz JI, Burrows AE, Ciccia A, Sun T, et al. 2011. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. *Proc. Natl. Acad. Sci. U. S. A.* 108:3665–3670.

Nichols B, Jog P, Lee JH, Blakker D, Wilmot M, D’Agati V, Markowitz G, Kopp JB, Alper SL, Pollak MR, et al. 2014. Innate immune pathways regulate the nephropathy gene Apolipoprotein L1. *Kidney Int.* 87:332–342.

O’Toole JF, Schilling W, Kunze D, Madhavan SM, Konieczkowski M, Gu Y, Luo L, Wu Z, Bruggeman LA, Sedor JR. 2018. ApoL1 overexpression drives variant-independent cytotoxicity. *J. Am. Soc. Nephrol.*

Olabisi OA, Zhang J-Y, VerPlank L, Zahler N, DiBartolo S, Heneghan JF, Schöndorff JS, Suh JH, Yan P, Alper SL, et al. 2016. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. *Proc. Natl. Acad. Sci. U. S. A.* 113:830–837.

Page NM, Butlin DJ, Lomthaisong K, Lowry PJ. 2001. The human apolipoprotein L gene cluster: Identification, classification, and sites of distribution. *Genomics* 74:71–78.

Page NM, Butlin DJ, Lomthaisong K, Lowry PJ. 2001. The human apolipoprotein L gene cluster: Identification, classification, and sites of distribution. *Genomics* 74:71–78.

Pays E, Vanhollebeke B, Uzureau P, Lecordier L, Pérez-Morga D. 2014. The molecular arms race between African trypanosomes and humans. *Nat. Rev. Microbiol.* 12:575–584.

Pays E, Vanhollebeke B, Vanhamme L, Patiaurides-Hancof F, Nolan DP, Perez-Morga D. 2006. The trypanolytic factor of human serum. *Nat. Rev. Microbiol.* 4:477–486.

Perez-Morga D, Vanhollebeke B, Patiaurides-Hancof F, Nolan DP, Lins L, Homblé F, Vanhamme L, Tebabi P, Pays A, Poelvoorde P, et al. 2005. Apolipoprotein L-I Promotes Trypanosome Lysis by Forming Pores in Lysosomal Membranes. *Science (80-. ).* 309:469–472.

Raper J, Fung R, Ghiso J, Nussenzweig V, Tomlinson S. 1999. Characterization of a novel trypanosome lytic factor from human serum. *Infect. Immun.* 67:1910–1916.

Reeves JR, O’Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, Xing CY, Ni L, Mathieson PW, Mundel P, et al. 2002. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. *J. Am. Soc. Nephrol.* 13:630–639.

Scales SJ, Gupta N, de Mazière AM, Posthuma G, Chiu CP, Pierce AA, Höltzel K, Tao J, Foreman O, Koukos G, et al. 2020. Apolipoprotein L1-Specific Antibodies Detect Endogenous APOL1 inside the Endoplasmic Reticulum and on the Plasma Membrane of Podocytes. *J. Am. Soc. Nephrol.*

Schaub C, Verdi J, Lee P, Terra N, Limon G, Raper J, Thomson R. 2020. Cation channel conductance and pH gating of the innate immunity factor APOL1 are governed by pore-independent cytotoxicity. *J. Am. Soc. Nephrol.*

Shah SS, Lannon H, Dias L, Zhang JY, Alper SL, Pollak MR, Friedman DJ. 2019. APOL1 kidney risk variants induce cell death via mitochondrial translocation and opening of the mitochondrial permeability transition pore. *J. Am. Soc. Nephrol.*

Shamas-Din A, Brahmabhatt H, Leber B, Andrews DW. 2011. BH3-only proteins: Orchestrators of apoptosis.
Biochim. Biophys. Acta - Mol. Cell Res. 1813:508–S20.
1. Shukla K, Mueller LL, Chung RT, Curry MP, Friedman DJ, Pollak MR, Berg AH. 2017. Most ApoL1 is secreted by the liver. J. Am. Soc. Nephrol.
2. De Simone G, Pasquadibisceglie A, Politicelli F, di Masi A, Ascenzi P. 2020. Haptoglobin and the related haptoglobin protein: the N-terminus makes the difference. J. Biomol. Struct. Dyn.
3. Smith EE, Malik HS. 2009. The apolipoprotein L family of programmed cell death and immunity genes rapidly evolved in primates at discrete sites of host-pathogen interactions. Genome Res. 19:850–858.
4. Sonnhammer EL, von Heijne G, Krogh A. 1998. A hidden Markov model for predicting transmembrane helices in protein sequences. Proc. Int. Conf. Intell. Syst. Mol. Biol. 6:175–182.
5. Thomson R, Finkelstein A. 2015. Human trypanolytic factor APOL1 forms pH-gated cation-selective channels in planar lipid bilayers: Relevance to trypanosome lysis. Proc. Natl. Acad. Sci. 112:2894–2899.
6. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekgn A, Bekele E, Bradman N, Wasser WG, Behar DM, et al. 2010. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum. Genet. 128:345–350.
7. Uzureau S, Lecordier L, Uzureau P, Hennig D, Graversen JH, Homblé F, Mfutu PE, Oliveira Arcolino F, Ramos AR, La Rovere RM, et al. 2020. APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3 Control of Actomyosin. Cell Rep. 30:3821-3836.e13.
8. Vanhamme L, Paturiaux U, Weide T, Chekuri A, Laatman E, van Manen R, Schmitt J, Wehr MC, Krahn MP, Koschmal N, Gromnitza S, Schulze H, Hennig D, Graversen JH, Homblé F, Mfutu PE, Oliveira Arcolino F, Ramos AR, Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekgn A, Bekele E, Bradman N, Wasser WG, Behar DM, et al. 2010. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum. Genet. 128:345–350.
9. Vanhollebeke B, Pays E. 2006. The function of apolipoproteins L. Cell. Mol. Life Sci. 63:1937–1944.
10. Velez JCC, Caza T, Larsen CP. 2020. COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nat. Rev. Nephrol.
11. Wakashin H, Heymann J, Roshanravan H, Daneshpajouhnejad P, Rosenberg A, Shin MK, Hoek M, Kopp JB. 2020. APOL1 renal risk variants exacerbate podocyte injury by increasing inflammatory stress. BMC Nephrol.
12. Wan G, Zhaorigetu S, Liu Z, Kaini R, Jiang Z, Hu CA. 2008. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J. Biol. Chem. 283:21540–21549.
13. Weckerle A, Snipes JA, Cheng D, Gebre AK, Reisz JA, Murea M, Shleness GS, Hawkins GA, Furdui CM, Freedman BI, et al. 2016. Characterization of circulating APOL1 protein complexes in African Americans. J. Lipid Res. 57:120–130.
14. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ. 2001. Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death. Science (80-. ). 292:727–730.
15. Wen H, Kumar V, Lan X, Shoshtari SSM, Eng JMM, Zhou X, Wang F, Wang H, Skorecki K, Xing G, et al. 2018. APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress. Biosci. Rep. 38:BSR20171713.
16. Wennmann DO, Schmitz J, Weide T, Chekuri A, Laatman E, van Manen R, Schmitt J, Wehr MC, Krahn MP, Koschmal N, Gromnitza S, Schulze H, Hennig D, Graversen JH, Homblé F, Mfutu PE, Oliveira Arcolino F, Ramos AR, Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekgn A, Bekele E, Bradman N, Wasser WG, Behar DM, et al. 2010. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum. Genet. 128:345–350.
17. Wiggins RC. 2007. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int.
18. Wiggins RC. 2007. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int.
19. Yang Z. 2007. PAML 4: Phylogenetic analysis by maximum likelihood. Mol. Biol. Evol.
20. Zhaorigetu S, Wan G, Kaini R, Jiang Z, Hu CAA. 2008. Apolipoprotein L6, induced in atherosclerotic lesions, promotes apoptosis and blocks beclin 1-dependent autophagy in atherosclerotic cells. J. Biol. Chem.
21. Zurek N, Sparks L, Voeltz G. 2011. Reticulon Short Hairpin Transmembrane Domains Are Used to Shape ER Tubules. Traffic 12:28–41.
**Figures and Figure legends**

**Figure 1:** Local APOL gene family and SplitsTree reconstructions for humans and mice.

**A:** Genomic location of APOL genes from human and mouse with genomic coordinates. Arrows indicate gene orientations. APOLD1 evolved early in vertebrates about 300 MYA, whereas APOL6 was probably inherited by a human-mouse ancestor that lived about 70 MYA. **B:** SplitsTree reconstruction of APOL genes based on protein sequences. A similar tree topology was derived by maximum likelihood and Bayesian tree reconstructions (SD1). The APOL genes of mice (mm for Mus musculus) are indicated in gray boxes. Black boxes represent human APOL genes (hs for Homo sapiens). The central parallelograms of the reconstruction represent conflicting phylogenetic signals. The tree reconstruction reveals a common origin of mm and hs APOL6 (red boxes). Bootstrap values are shown for representative branches. Balls indicate the clade-supporting integrations of AluJ and AluY elements.

The human APOL2 and APOL1 genes share an orthologous AluY element. The orthologous AluY transposons were already present in Catharine primates (diverged about 30 MYA). The diagnostic AluJ elements were detected at orthologous positions in APOL1-4 in all investigated primates and were probably inherited from a common primate ancestor of about 70 MYA. The double-slash in the mouse locus indicates the exclusion of a large genomic region. Human and mouse APOLD1 are located on chromosome 12 and 6, respectively, and diverged significantly from other APOL genes.
**Figure 2: APOL1 isoforms and related APOL gene members.**

**A:** Gene structures of the four well-characterized APOL1 isoforms vA, vB1, vB3, and vC (Khatua et al. 2015). Exons for APOL1 vA (gene size ~14 kb) are labeled 1-7. White frames indicate UTR regions. Black boxes represent leading signal peptides, gray boxes the remaining protein-coding exons, and black lines the intronic regions. Start codons are indicated by triangles and stop codons by asterisks.

**B:** Cumulative gene structures of all human APOL gene members and isoforms. Red arrows indicate the insertion points of three diagnostic transposable elements (AluJ merging APOL1-4, MER41G representing alternative exon insertion/exonization in APOL4, AluY indicating a common ancestry of APOL1-2). Highly diverged sequences are shown by dotted lines (annotated alignments are provided as SD4).
Figure 3: APOL1-APOL2 gene diversification is accompanied by organ-specific expression.

A: Expression levels of APOL1 (L1, green) and APOL2 (L2, orange) transcriptomes (expressed as reads per kilobase transcript per million (RPKM)-normalized counts) during human organ development derived from the Evo-devo database. White background indicates embryonic or prenatal stages and gray background postnatal stages of mammalian organ development (SD20).
Figure 4: APOL1 splice variants and APOL2 are targeted to the ER.

A: Schemes of C-terminally GFP-tagged APOL1 splice variants, GFP-APOL1 (lacking the SP, ΔSP, aa1-27), and N-terminally GFP- or RFP-tagged APOL2. B-G: Live cell imaging of AB8 podocytes, expressing APOL1-GFP splice variants vA, vB1, vB3 and vC (B-E), GFP-APOL2 (F), or GFP-tagged APOL1 together with RFP-APOL2 (G). ER membranes are visualized with live-cell imaging dye ER Tacker.

Scale Bars: 20 μm.
Figure 5: Different ER insertion orientations accompany APOL1-APOL2 diversification.

A: The endogenous SP of the reporter enzyme SEAP (secreted alkaline phosphatase, gray box) was replaced by the N-termini of the APOL1 splice variants (vA, vB1, vB3, vC). The endogenous SP of SEAP (SP\textsubscript{SEAP}) and the well-known SP of human serum albumin (SP\textsubscript{HSA}) served as positive, and SEAP lacking its SP (ΔSP) as negative control. B: SEAP secretion assay in HEK293T cells. Fluorescent SEAP secretion was detectable for positive controls (SP\textsubscript{SEAP} and SP\textsubscript{HSA}) and splice variants vA, vB1, and vC. SEAP with the N-termini of APOL1 vB3 and without the SEAP signal peptide (ΔSP) were not secreted (***p<0.0001).

C: Scheme: APOL1 splice variants vA, vB1, vB3, vC, a mutant lacking the complete APOL1 N-terminus (aa1-59; ΔN59), and APOL2 were fused with an artificial C-terminal N-glycosylation tag (GT). D: Western blot analyses of Glyco-tag (GT) APOL proteins (shown in C) before and after PNGaseF glycosidase digestion showed N-glycosylation and therefore ER luminal localization only for APOL1 vB1, and vC (marked by black asterisks). E: Scheme: C-terminally GFP-tagged APOL1 (G0 and renal risk variants G1 and G2), APOL1 lacking C-terminal aa 305-398 (ΔC305) and APOL2. F: Western blot analysis of these GFP-GT-tagged proteins (shown in E) before and after PNGaseF glycosidase digestion demonstrate luminal ER localization for these proteins (asterisks), except for APOL2-GFP-GT.
Figure 6: APOL1 cytotoxicity is caused by cis- and trans-orientated APOL1 pools.

A: Schemes of APOL1 variants used for cell viability assays. Left panel: We used APOL1 G0, and renal risk variants G1 and G2 combined with C-terminal GFP (APOL1-GFP, vA aa1-398), and APOL1 fusion proteins (G0, G1 and G2) in which the APOL1 SP was replaced by an N-terminal GFP-tag (GFP-APOL1 ΔSP; aa28-398). Right panel: To analyze the impact of the putative pro-apoptotic “BH3-only motif” (BSM) in APOL1 pools at the outer ER membrane (trans orientation), we replaced the BSM of GFP-APOL1 by either an Alanine stretch (B6xAla) or by the BSM of APOL2 (B2). GFP-tagged APOL2 was used as a control.

B: Cell viability assay of stable HEK293T cell lines expressing proteins summarized in A: APOL1-expressing cell lines, particularly those with RRVs, exhibited cytotoxic effects in cis- and trans-orientations. Toxic GFP-APOL1 (ΔSP, G2) in which the BSM was replaced by Alanine (GFP-APOL1 ΔSP B6xAla) or the BSM of APOL2 (GFP-APOL1 B2) and GFP-APOL2 showed no cytotoxicity (***p<0.0001).
Figure 7: APOL1 vA gene structure and regions with positively selected sites.

A: Amino acids (single letter code) and coordinates mark positively selected sites for APOL1-4 derived from at least two of three PAML models (M2/M8/BS) as large stars. The positively selected sites found by Smith and Malik (2009) are indicated for APOL1-2, APOL3-4, and APOL6. Red labeled letters show overlapping sites of different studies. The APOL1 variations of (alternative amino acids or deletion sites, Δ) are shown above the exon structure (gray). APOL1 was previously divided into four functional regions, a signal peptide (SP), a pore-forming domain (PFD), a membrane addressing domain (MAD), and the SRA-interacting-protein-like domain (SID) (green boxes). The PFD also contains a putative pro-apoptotic BH3-only domain sequence motif (BSM). More recent conceptions suggest a SP (gray bar) and up to four transmembrane regions (SP, grey and TM1-4, black bars with their coordinates indicated as numbers). The first two TMs are also referred to as membrane insertion domain (MID) or helix-turn-helix region (H-L-H). The TM4 overlaps with a pore-lining region (PLR), followed by leucine-zipper domain (ZIP).

B: Model of possible orientations of APOL1 (and APOL2) at the ER. The presence or absence of the signal peptide determines the orientation of APOL1 splice variants and of APOL2 at the ER. Functional SPs result in a luminal (cis) ER localization of the APOL1 C-terminus. If APOL1 functions as an ion pore, this most likely requires two (I), “two and a half” (II) or four (III) transmembrane regions (black boxes). During evolution, positively selected amino acids accumulate in regions within, or close to, the putative TM3 and TM4 (red arrows). APOL1 vB3 and APOL2, that lack functional SPs (IV), are most likely bound to the cytoplasmic leaflet of the ER membrane (trans). Since cis as well as trans pools of APOL1 show cytotoxic effects - that are pronounced in the case of renal risk variants – our data suggest the presence of different cellular pathomechanisms.